New chimeric antigen receptor design for solid tumors
Open accessAbstract
In recent years, chimeric antigen receptor (CAR) T-cell therapy has become popular in immunotherapy, particularly after its tremendous success in the treatment of lineage-restricted hematologic cancers. However, the application of CAR T-cell therapy for solid tumors has not reached its full potential because of the lack of specific tumor antigens and inhibitory factors in suppressive tumor microenvironment (TME) (e.g., programmed death ligand-1, myeloid-derived suppressor cells, and transforming growth factor-β). In this review, we include some limitations in CAR design, such as tumor heterogeneity, indefinite spatial distance between CAR T-cell and its target cell, and suppressive TME. We also summarize some new approaches to overcome these hurdles, including targeting neoantigens and/or multiple antigens at once and depleting some inhibitory factors.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The identification of tumor-specific antigens (TSAs) is unusual.
“the identification of tumor-specific antigens (TSAs) is unusual [139]”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [139]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994 · see citing works
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148 · see citing works
Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,542 · see citing works
Self-citationRegression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610497 · Cited by 1,842 · see citing works
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815 · see citing works
Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766 · see citing works
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688 · see citing works
Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,668 · see citing works
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W.-R., Hildebrand, W. H., Mardis, E. R., et al. (2015) · Science · doi:10.1126/science.aaa3828 · Cited by 1,285 · see citing works
Kawalekar, O. U., O’Connor, R. S., Fraietta, J. A., Guo, L., McGettigan, S. E., Posey, A. D., Patel, P. R., Guedan, S., Scholler, J., Keith, B., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.021 · Cited by 1,234 · see citing works
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 1,151 · see citing works
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Cherkassky, L., Morello, A., Villena‐Vargas, J., Feng, Y., Dimitrov, D. S., Jones, D. R., Sadelain, M., & Adusumilli, P. S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83092 · Cited by 1,075 · see citing works
Ahmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0225 · Cited by 1,004 · see citing works
Lamers, C. H. J., Sleijfer, S., Vulto, A. G., Kruit, W. H. J., Kliffen, M., Debets, R., Gratama, J. W., Stoter, G., & Oosterwijk, E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9964 · Cited by 915 · see citing works
CAR T Cell Therapy for Solid Tumors
Newick, K., O'Brien, S., Moon, E., & Albelda, S. M. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-062315-120245 · Cited by 909 · see citing works
Beatty, G. L., Haas, A. R., Maus, M. V., Torigian, D. A., Soulen, M. C., Plesa, G., Chew, A., Zhao, Y., Levine, B. L., Albelda, S. Μ., et al. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0170 · Cited by 867 · see citing works
Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M. P., & Sadelain, M. (2012) · Nature Biotechnology · doi:10.1038/nbt.2459 · Cited by 860 · see citing works
Gros, A., Parkhurst, M. R., Tran, E., Pasetto, A., Robbins, P. F., Ilyas, S., Prickett, T. D., Gartner, J. J., Crystal, J. S., Roberts, I. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4051 · Cited by 830 · see citing works
Self-citationBrown, C. E., Badie, B., Barish, M. E., Weng, L., Ostberg, J. R., Chang, W.-C., Naranjo, A., Starr, R., Wagner, J. R., Wright, C. L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0428 · Cited by 766 · see citing works
Immunogenicity of somatic mutations in human gastrointestinal cancers
Tran, E., Ahmadzadeh, M., Lu, Y.-C., Gros, A., Turcotte, S., Robbins, P. F., Gartner, J. J., Zheng, Z., Li, Y. F., Ray, S., et al. (2015) · Science · doi:10.1126/science.aad1253 · Cited by 729 · see citing works
Lamers, C. H., Sleijfer, S., van Steenbergen, S. C. L., van Elzakker, P., Krimpen, B. A. V., Groot, C., Vulto, A. G., den Bakker, M., Oosterwijk, E., Debets, R., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.17 · Cited by 706 · see citing works
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies
Anderson, K. G., Stromnes, I. M., & Greenberg, P. D. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.008 · Cited by 706 · see citing works
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
Hegde, M. G., Mukherjee, M., Grada, Z., Pignata, A., Landi, D. B., Navai, S. A., Wakefield, A., Fousek, K., Bielamowicz, K., Chow, K. K. H., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83416 · Cited by 681 · see citing works
Liu, X., Jiang, S., Fang, C., Yang, S., Olalere, D., Pequignot, E. C., Cogdill, A. P., Li, N., Ramones, M., Granda, B. W., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0159 · Cited by 566 · see citing works
The kinetic-segregation model: TCR triggering and beyond
Davis, S. J., & van der Merwe, P. A. (2006) · Nature Immunology · doi:10.1038/ni1369 · Cited by 562 · see citing works
Moon, E. K., Carpenito, C., Sun, J., Wang, L. S., Kapoor, V., Predina, J. D., Powell, D. J., Riley, J. L., June, C. H., & Albelda, S. Μ. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0351 · Cited by 537 · see citing works
Hudecek, M., Sommermeyer, D., Kosasih, P. L., Silva-Benedict, A., Liu, L., Rader, C. M., Jensen, M. C., & Riddell, S. R. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0127 · Cited by 534 · see citing works
Design and development of therapies using chimeric antigen receptor‐expressing T cells
Dotti, G., Gottschalk, S. M., Savoldo, B., & Brenner, M. K. (2013) · Immunological Reviews · doi:10.1111/imr.12131 · Cited by 510 · see citing works
Engineering CAR-T cells: Design concepts
Srivastava, S., & Riddell, S. R. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.06.004 · Cited by 489 · see citing works
Ciceri, F., Bonini, C., Stanghellini, M. T. L., Bondanza, A., Traversari, C., Salomoni, M., Turchetto, L., Colombi, S., Bernardi, M., Peccatori, J., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70074-9 · Cited by 485 · see citing works
Neoantigen landscape dynamics during human melanoma–T cell interactions
Verdegaal, E. M. E., de Miranda, N. F. C. C., Visser, M., Harryvan, T. J., van Buuren, M. M., Andersen, R. S., Hadrup, S. R., van der Minne, C. E., Schotte, R., Spits, H., et al. (2016) · Nature · doi:10.1038/nature18945 · Cited by 464 · see citing works
Johnson, L. A., Scholler, J., Ohkuri, T., Kosaka, A., Patel, P. R., McGettigan, S. E., Nace, A., Dentchev, T., Thekkat, P. U., Loew, A., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4963 · Cited by 452 · see citing works
'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations
Tran, E., Robbins, P. F., & Rosenberg, S. A. (2017) · Nature Immunology · doi:10.1038/ni.3682 · Cited by 443 · see citing works
Mesothelin-Targeted CARs: Driving T cells to Solid Tumors
Morello, A., Sadelain, M., & Adusumilli, P. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0583 · Cited by 420 · see citing works
Katz, S. C., Burga, R. A., McCormack, E. M., Wang, L., Mooring, W., Point, G. R., Khare, P. D., Thorn, M., Ma, Q., Stainken, B. F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1421 · Cited by 397 · see citing works
Beatson, R., Tajadura‐Ortega, V., Achkova, D., Picco, G., Tsourouktsoglou, T.-D., Klausing, S., Hillier, M. C. J., Maher, J. F., Noll, T., Crocker, P. R., et al. (2016) · Nature Immunology · doi:10.1038/ni.3552 · Cited by 379 · see citing works
Prospects for gene-engineered T cell immunotherapy for solid cancers
Klebanoff, C. A., Rosenberg, S. A., & Restifo, N. P. (2016) · Nature Medicine · doi:10.1038/nm.4015 · Cited by 366 · see citing works
ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells
Guedan, S., Chen, X., Madar, A., Carpenito, C., McGettigan, S. E., Frigault, M. J., Lee, J., Posey, A. D., Scholler, J., Scholler, N., et al. (2014) · Blood · doi:10.1182/blood-2013-10-535245 · Cited by 348 · see citing works
Antitumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma
Kakarla, S., Chow, K. K. H., Mata, M., Shaffer, D. R., Song, X., Wu, M.-F., Liu, H., Wang, L. L., Rowley, D. R., Pfizenmaier, K., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.110 · Cited by 347 · see citing works
Suarez, E. R., Chang, D.-K., Sun, J., Sui, J., Freeman, G. J., Signoretti, S., Zhu, Q. K., & Marasco, W. A. (2016) · Oncotarget · doi:10.18632/oncotarget.9114 · Cited by 339 · see citing works
Nishio, N., Diaconu, I., Liu, H., Cerullo, V., Caruana, I., Hoyos, V., Bouchier‐Hayes, L., Savoldo, B., & Dotti, G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0697 · Cited by 330 · see citing works
Biophysical mechanism of T-cell receptor triggering in a reconstituted system
James, J. R., & Vale, R. D. (2012) · Nature · doi:10.1038/nature11220 · Cited by 324 · see citing works
Ninomiya, S., Narala, N., Huye, L. E., Yagyu, S., Savoldo, B., Dotti, G., Heslop, H. E., Brenner, M. K., Rooney, C. M., & Ramos, C. A. (2015) · Blood · doi:10.1182/blood-2015-01-621474 · Cited by 317 · see citing works
Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma
Gao, H., Li, K., Tu, H., Pan, X., Jiang, H., Shi, B., Kong, J., Wang, H., Yang, S., Gu, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1170 · Cited by 313 · see citing works
Immunotherapy and tumor microenvironment
Tang, H., Qiao, J., & Fu, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.10.009 · Cited by 306 · see citing works
Initiation of T cell signaling by CD45 segregation at 'close contacts'
Chang, V. T.-C., Fernandes, R. A., Ganzinger, K. A., Lee, S. F., Siebold, C., McColl, J. T., Jönsson, P., Palayret, M., Harlos, K., Coles, C. H., et al. (2016) · Nature Immunology · doi:10.1038/ni.3392 · Cited by 292 · see citing works
Feng, K., Guo, Y., Dai, H., Wang, Y., Li, X., Jia, H., & Han, W. (2016) · Science China Life Sciences · doi:10.1007/s11427-016-5023-8 · Cited by 290 · see citing works
Self-citationJunghans, R. P., Ma, Q., Rathore, R., Gomes, E. M., Bais, A. J., Lo, A. S. Y., Abedi, M., Davies, R. A., Cabral, H. J., Al‐Homsi, A. S., et al. (2016) · The Prostate · doi:10.1002/pros.23214 · Cited by 267 · see citing works
Schneider, D., Xiong, Y., Wu, D., Nölle, V., Schmitz, S. M., Haso, W. M., Kaiser, A., Dropulić, B., & Orentas, R. J. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0246-1 · Cited by 263 · see citing works
Han, W., Pan, H., Chen, Y., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018691 · Cited by 256 · see citing works
Diaconu, I., Ballard, B. C., Zhang, M., Chen, Y., West, J., Dotti, G., & Savoldo, B. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.01.011 · Cited by 251 · see citing works
Burga, R. A., Thorn, M., Point, G. R., Guha, P., Nguyen, C. T., Licata, L. A., DeMatteo, R. P., Ayala, A., Espat, N. J., Junghans, R. P., et al. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1692-6 · Cited by 230 · see citing works
Curran, K. J., Seinstra, B. A., Nikhamin, Y., Yeh, R., Usachenko, Y., van Leeuwen, D. G., Purdon, T. J., Pegram, H. J., & Brentjens, R. J. (2015) · Molecular Therapy · doi:10.1038/mt.2015.4 · Cited by 217 · see citing works
Zhang, H., Snyder, K. M., Suhoski, M. M., Maus, M. V., Kapoor, V., June, C. H., & Mackall, C. L. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.7.4910 · Cited by 202 · see citing works
Scarfò, I., & Maus, M. V. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0230-9 · Cited by 191 · see citing works
Erratum: The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.65 · Cited by 191 · see citing works
McNeill, L., Salmond, R. J., Cooper, J. C., Carret, C., Cassady-Cain, R. L., Roche-Molina, M., Tandon, P., Holmes, N., & Alexander, D. R. (2007) · Immunity · doi:10.1016/j.immuni.2007.07.015 · Cited by 189 · see citing works
CD45 ectodomain controls interaction with GEMs and Lck activity for optimal TCR signaling
Irles, C., Symons, A., Michel, F., et al. (2002) · Nature Immunology · doi:10.1038/ni877 · Cited by 179 · see citing works
CAR–T cells and solid tumors: tuning T cells to challenge an inveterate foe
Gilham, D. E., Debets, R., Pulè, M. A., Hawkins, R. E., & Abken, H. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.04.009 · Cited by 179 · see citing works
CAR-T Cell Therapy for Lymphoma
Ramos, C. A., Heslop, H. E., & Brenner, M. K. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051914-021702 · Cited by 172 · see citing works
Hermiston, M. L., Zikherman, J., & Zhu, J. W. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00752.x · Cited by 170 · see citing works
Early T Cell Activation: Integrating Biochemical, Structural, and Biophysical Cues
MALISSEN, B., & Bongrand, P. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112158 · Cited by 152 · see citing works
Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
John, L. B., Kershaw, M., & Darcy, P. (2013) · Oncoimmunology · doi:10.4161/onci.26286 · Cited by 139 · see citing works
CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy
Chen, N., Morello, A., Tano, Z. E., & Adusumilli, P. S. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1273302 · Cited by 134 · see citing works
Integrative biology of T cell activation
MALISSEN, B., Grégoire, C., Malissen, M., & Roncagalli, R. (2014) · Nature Immunology · doi:10.1038/ni.2959 · Cited by 131 · see citing works
Improving the safety of cell therapy with the TK-suicide gene
Greco, R., Oliveira, G., Stanghellini, M. T. L., Vago, L., Bondanza, A., Peccatori, J., Cieri, N., Marktel, S., Mastaglio, S., Bordignon, C., et al. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00095 · Cited by 116 · see citing works
Cordoba, S., Choudhuri, K., Zhang, H., Bridge, M., Basat, A. B., Dustin, M. L., & van der Merwe, P. A. (2013) · Blood · doi:10.1182/blood-2012-07-442251 · Cited by 109 · see citing works
Li, W., Guo, L., Rathi, P., Marinova, E., Gao, X., Wu, M.-F., Liu, H., Dotti, G., Gottschalk, S. M., Metelitsa, L. S., et al. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.025 · Cited by 107 · see citing works
Myeloid-derived suppressor cells and their role in pancreatic cancer
Pergamo, M., & Miller, G. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.65 · Cited by 106 · see citing works
Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors
Zhang, B., Qin, D., Mo, Z., Li, Y., Wei, W., Wang, Y., Wang, W., & Wei, Y.-Q. (2016) · Science China Life Sciences · doi:10.1007/s11427-016-5027-4 · Cited by 105 · see citing works
Self-citationHombach, A. A., Schildgen, V., Heuser, C., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4650 · Cited by 104 · see citing works
Zhang, Y., & Ertl, H. C. J. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00032 · Cited by 100 · see citing works
Xie, X., Zhao, X., Liu, Y., et al. (2001) · PubMed · Cited by 93 · see citing works
Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade
Serganova, I. S., Moroz, E., Cohen, I., Moroz, M. A., Mane, M. M., Zurita, J., Shenker, L., Ponomarev, V., & Blasberg, R. G. (2016) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2016.11.005 · Cited by 93 · see citing works
Kuo, W.-Y., Hwu, L., Wu, C.-Y., Lee, J.-S., Chang, C., & Liu, R.-S. (2017) · Theranostics · doi:10.7150/thno.16827 · Cited by 92 · see citing works
The breast tumor microenvironment alters the phenotype and function of natural killer cells
Krneta, T., Gillgrass, A. E., Chew, M. V., & Ashkar, A. A. (2015) · Cellular and Molecular Immunology · doi:10.1038/cmi.2015.42 · Cited by 88 · see citing works
Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection
Zhukovsky, E. A., Morse, R. J., & Maus, M. V. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.02.006 · Cited by 85 · see citing works
Nishio, N., & Dotti, G. (2015) · OncoImmunology · doi:10.4161/21505594.2014.988098 · Cited by 83 · see citing works
Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don’t Forget the Fuel
Irving, M. B., de Silly, R. V., Scholten, K. B. J., Dilek, N., & Coukos, G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00267 · Cited by 74 · see citing works
Nutrient Sensing via mTOR in T Cells Maintains a Tolerogenic Microenvironment
Howie, D., Waldmann, H., & Cobbold, S. P. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00409 · Cited by 57 · see citing works
CD45-mediated control of TCR tuning in naïve and memory CD8+ T cells
Cho, J.-H., Kim, H.-O., Ju, Y.-J., Kye, Y.-C., Lee, G.-W., Lee, S.-W., Yun, C., Bottini, N., Webster, K. E., Goodnow, C. C., et al. (2016) · Nature Communications · doi:10.1038/ncomms13373 · Cited by 52 · see citing works
Ablation of microvessels in vivo upon dimerization of iCaspase-9
Nör, J., Hu, Y., Song, W., et al. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301671 · Cited by 49 · see citing works
A proangiogenic signaling axis in myeloid cells promotes malignant progression of glioma
Huang, Y., Rajappa, P., Hu, W., Hoffman, C. E., Cisse, B., Kim, J. H., Gorge, E., Yanowitch, R. N., Cope, W., Vartanian, E. D., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci86443 · Cited by 45 · see citing works
Targeting of Tumor-Associated Glycoforms of MUC1 with CAR T Cells
Maher, J. F., Wilkie, S., Davies, D. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.014 · Cited by 41 · see citing works
Li, K., Pan, X., Bi, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6595 · Cited by 34 · see citing works
Posey, A. D., Clausen, H., & June, C. H. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.015 · Cited by 34 · see citing works
Sui, X., Kong, N., Zhu, M., et al. (2013) · Molecular and Clinical Oncology · doi:10.3892/mco.2013.187 · Cited by 31 · see citing works
Luo, F., Qian, J., Yang, J., et al. (2016) · Cell Research · doi:10.1038/cr.2016.81 · Cited by 27 · see citing works
Self-citationiCaspase 9 Suicide Gene System
Zhou, X., Stasi, A. D., & Brenner, M. K. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2727-2_6 · Cited by 25 · see citing works
Designing CAR T cells for glioblastoma
Maus, M. V. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1048956 · Cited by 22 · see citing works
Huang, C., Wang, H., Liao, W., Han, F., Li, Y., Chen, S.-W., & Lao, X. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000166 · Cited by 19 · see citing works
Combinatorial Antigen Targeting: Ideal T-Cell Sensing and Anti-Tumor Response
Themeli, M., & Sadelain, M. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.02.009 · Cited by 13 · see citing works
Chendeb, M., Schneider, R., Davidson, I., & Fadloun, A. (2017) · Oncotarget · doi:10.18632/oncotarget.16013 · Cited by 6 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy
Nikolouzakis, T. K., Chrysos, E., Docea, A. O., Fragkiadaki, P., Souglakos, J., Tsiaoussis, J., & Tsatsakis, A. (2024) · Cancers · doi:10.3390/cancers16111995 · Cited by 37 · see citing works
Advances in adoptive cellular therapy for colorectal cancer: A narrative review
Yi, X., & Hu, W. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-6196 · Cited by 14 · see citing works
- Authors
- Wang, Y., Luo, F., Yang, J., Zhao, C., & Chu, Y.
- Affiliations
- Shanghai Medical College of Fudan University (CN)
- Fudan University (CN)
- Corresponding author
- Chu, Yiwei
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2017-12-22
- Volume
- 8
- Pages
- 1934-1934
- ISSN
- 1664-3224 (ISSN-L)
- PMC
- PMC5744429
- OpenAlex
- W2780966256
- Cited by
- 32
- References
- 93
- Citations by year
- 2026: 1 · 2024: 2 · 2023: 1 · 2022: 3 · 2021: 4 · 2020: 12 · 2019: 4 · 2018: 5
- FWCI
- 0.60
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Frontiers in Immunology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (31400772, 91527305, 81730045)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- CAR T-cell therapy, solid tumors, tumor microenvironment, PD-L1, myeloid-derived suppressor cells, TGF-beta, tumor heterogeneity, multi-antigen targeting, automotive design
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
